NCT06291597 Vaping Adverse Lung and Heart Events Cohort
| NCT ID | NCT06291597 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Laval University |
| Condition | Vaping |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2021-10-14 |
| Primary Completion | 2031-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2021-10-14 with a primary completion date of 2031-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective study assesses the pulmonary and cardiovascular effets of vaping in adult electronic cigarette users with biannual visits and a 5-year follow-up.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Daily electronic cigarette user * No respiratory infection in the 4 weeks before a visit Exclusion Criteria: * Women who are pregnant or breast-feeding.
Contact & Investigator
Mathieu C Morissette, PhD
PRINCIPAL INVESTIGATOR
Laval University
Frequently Asked Questions
Who can join the NCT06291597 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Vaping. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06291597 currently recruiting?
Yes, NCT06291597 is actively recruiting participants. Contact the research team at ariane.lechasseur@criucpq.ulaval.ca for enrollment information.
Where is the NCT06291597 trial being conducted?
This trial is being conducted at Québec, Canada.
Who is sponsoring the NCT06291597 clinical trial?
NCT06291597 is sponsored by Laval University. The principal investigator is Mathieu C Morissette, PhD at Laval University. The trial plans to enroll 250 participants.